小剂量他达拉非联合疏肝益阳胶囊治疗轻中度勃起功能障碍的疗效分析

目的:观察每日1次小剂量他达拉非联合疏肝益阳胶囊治疗轻中度勃起功能障碍(ED)的临床疗效。方法:将90例轻中度ED患者随机分为疏肝益阳胶囊组(A组)、他达拉非组(B组)、他达拉非联合疏肝益阳胶囊组(C组)(每组各30例),于治疗前、治疗后第1月末和治疗后第3月末分别记录3组IIEF-5、简化式(15项)的心理和人际关系量表(SF-PAIRS)等各项积分,并观察疗效变化。结果:①3组治疗前IIEF-5评分依次为(10.13±1.55)、(11.00±1.60)、(10.73±1.91)分,3组相比差异均无统计学意义(P均0.05);治疗后第1个月末评分分别为(13.77±2.11)、(17.77±2.13)、(17.17±3.84)分,B组与C组无差别(P=0.411),但两组均优于A组,差异具有显著性(P0.001);治疗后第3个月末评分分别为(15.77±2.05)、(18.07±2.24)、(19.37±3.76)分,B组与C组均优于A组(P均0.001),C组优于B组(P0.05)。②A组治疗前SF-PAIRS的性自信、性自然指数、时间顾虑等3方面评分分别为(3.90±0.80,8.67±1.94,14.43±1.92),治疗后第1个月末评分分别为(5.83±1.02)、(9.90±1.75)、(11.17±1.68)分,治疗后第3个月末评分分别为(6.73±0.98)、(11.07±2.08)、(10.67±1.60)分;B组治疗前SF-PAIRS的性自信、性自然指数、时间顾虑等3方面评分分别为(4.17±0.87)、(9.37±1.43)、(14.47±1.57)分,治疗后第1个月末评分分别为(6.47±0.78)、(10.83±2.18)、(10.20±1.56)分,治疗后第3个月末评分分别为(6.83±0.91)、(11.30±1.88)、(9.47±1.57)分;C组治疗前SF-PAIRS的性自信、性自然指数、时间顾虑等3方面评分分别为(4.23±0.94)、(9.50±1.89)、(14.67±2.91)分,治疗后第1个月末评分分别为(8.03±1.67)、(13.43±1.10)、(9.70±1.21)分,治疗后第3个月末评分分别为(8.93±1.78)、(14.70±1.26)、(8.87±0.97)分。3组的SF-PAIRS评分治疗后各自较治疗前均有改善,差异具有统计学意义(P0.05);且治疗后C组的3方面评分与A、B两组相比差异均有统计学意义(P0.05)。结论:每日1次小剂量他达拉非联合疏肝益阳胶囊治疗ED不但能有效提高ED患者勃起功能,而且能显著增强患者性自信和性自然程度,同时减少时间顾虑,具有良好的临床疗效。

Low.dose tadalafil combined with Shuganyiyang Capsules for mild-to-moderate erectile dysfunction

To observe the clinical effect of low-dose once-daily tadalafil combined with Shuganyiyang Capsules in the treatment of mild-to-moderate erectile dysfunction （ED）. Methods ： Ninety patients with mild-to-moderate ED were equally ran- domized to groups A, B and C to receive Shuganyiyang Capsules, tadalafil, and tadalafil ± Shuganyiyang Capsules, respectively. The scores of the patients on IIEF-5 and SF-PAIRS （15-Item Short Form of Psychological Interpersonal Relationship Scales） were re-corded before and at 1 and 3 months after treatment. Results ： The IIEF-5 scores of groups A, B and C were 10.13 =t= 1.55, 11. O0 ± 1.60 and 10.73 ± 1.91 before treatment, and 13.77 ±-2.11, 17.77 -± 2.13 and 17.17 -± 3.84 at 1 month after treatment, significantly higher in B and C than in A （P 〈0.001 ） , but with no remarkable difference between B and C （P =0.411 ）. At 3 months after treat- ment, the IIEF-5 scores were 15.77 ± 2.05, 18.07 ± 2.24 and 19.37 ± 3.76 in the three groups, dramatically higher in B and C than in A （ P 〈 0. 001 ） as well as in C than in B （ P 〈 0.05 ）. The scores on sexual self-confidence, sexual spontaneity and time concerns in SF-PAIRS were 3.90 ± 0.80, 8.67 ± 1.94 and 14.43 -± 1.92 before medication, 5.83 ± 1.02, 9.90 ± 1.75 and 11.17 ± 1.68 at 1 month and 6.73 ± O. 98, 11.07 ± 2.08 and 10.67 ± 1.60 at 3 months after medication in group A; 4.17 ± 0. 87, 9.37 ± 1.43 and 14.47 ± 1.57 before medication, 6.47 ± 0. 78, 10.83 ± 2.18 and 10.20 ± 1.56 at 1 month and 6.83 ± 0.91, 11.30 ± 1.88 and 9.47 ± 1.57 at 3 months in group B ; and 4.23 ± 0.94, 9.50 ± 1.89 and 14.67 ± 2.91 before medication, 8.03 ± 1.67, 13.43 ± 1.10 and 9.70 ± 1.21 at 1 month and 8.93 -± 1.78, 14.70 ± 1.26 and 8.87 ± 0.97 at 3 months in group C. Compared with the baseline, the SF-PAIRS scores of the three groups were all significantly improved after treatment （ P 〈 0.05 ） , and markedly higher in C than in the other two groups （ P 〈 O. 05 ）. Conclusion ： Low-dose once-daily tadalafil combined with Shuganyiyang Capsules is obviously effec- tive in the treatment of mild-to-moderate ED, which not only improves the patients＇erectile function, sexual self-confidence and sexual spontaneity, but also reduces their time concerns. Natl J Androl, 2014, 20 （3） ： 267-272